Wednesday, July 04, 2018 7:48:43 PM
NO!
CELZ adheres to a strict model of using only the highest potency Stem Cells which are Adult Derived Bone Marrow Mesenchymal Stem Cells and taking absolute measures to NOT adulterate any of it so as to adhere to "not a drug" definition set by FDA.
Then, the administer this Adult Derived Bone Marrow Mesenchymal Stem Cells to the same patient During the same procedure so that they are protected by CFR 721 which I posted earlier:
Part 1271--Human cells, Tissues, and Cellular and tissue-based products
Sec. 1271015 are there any exceptions from the requirements of this part?
(b) "you are not required to comply with the requirements of this part if you are an establishment that removes HCT/P's from an individual and implants such HCT/P's into the same individual during the same surgical procedure."
CELZ adheres to a strict model of using only the highest potency Stem Cells which are Adult Derived Bone Marrow Mesenchymal Stem Cells and taking absolute measures to NOT adulterate any of it so as to adhere to "not a drug" definition set by FDA.
Then, the administer this Adult Derived Bone Marrow Mesenchymal Stem Cells to the same patient During the same procedure so that they are protected by CFR 721 which I posted earlier:
Part 1271--Human cells, Tissues, and Cellular and tissue-based products
Sec. 1271015 are there any exceptions from the requirements of this part?
(b) "you are not required to comply with the requirements of this part if you are an establishment that removes HCT/P's from an individual and implants such HCT/P's into the same individual during the same surgical procedure."
My research and my opinion. My opinions is not a recommendation to buy or sell a security. Your decision whether or not to make a purchase should be based on your own due diligence.
Recent CELZ News
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/20/2026 08:45:28 PM
- Creative Medical Technology Holdings Achieves Second WHO INN Milestone, Strengthening Global Regulatory Positioning Across Expanding Cell Therapy Pipeline • GlobeNewswire Inc. • 02/10/2026 02:00:00 PM
- Creative Medical Technology Holdings Reaches Major Clinical Inflection Point with Positive Interim Data from ADAPT Trial and CELZ-201 (Olastrocel) in the Treatment of Chronic Lower Back Pain • GlobeNewswire Inc. • 01/13/2026 02:15:00 PM
- Creative Medical Technology Holdings Receives Regulatory Approval for BioDefense Burn Pit Initiative • GlobeNewswire Inc. • 01/06/2026 02:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/31/2025 09:05:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2025 09:01:58 PM
- Creative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared ADAPT Trial for CELZ-201-Olastrocel, Marking Major Clinical Inflection Point • GlobeNewswire Inc. • 12/17/2025 02:15:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/16/2025 09:05:24 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/15/2025 05:15:26 AM
- Creative Medical Technology Holdings Announces World Health Organization Approval of “olastrocel” as INN for Lead Allogeneic Cell Therapy CELZ-201 • GlobeNewswire Inc. • 12/02/2025 02:15:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 11/21/2025 09:31:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 11:12:58 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/07/2025 09:46:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 08:05:42 PM
- Creative Medical Technology Holdings, Inc. Ignites Next-Gen Regenerative BioDefense Initiative for U.S. Veterans Exposed to Burn Pits • GlobeNewswire Inc. • 10/30/2025 01:15:00 PM
- Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.2 Million Gross Proceeds • GlobeNewswire Inc. • 10/29/2025 01:00:00 PM
- Creative Medical Technology Holdings Issues Letter to Shareholders • GlobeNewswire Inc. • 10/27/2025 12:15:00 PM
- Creative Medical Technology Holdings Congratulates 2025 Nobel Laureates for Regulatory T Cell Breakthroughs • GlobeNewswire Inc. • 10/07/2025 01:15:00 PM
- Creative Medical Technology Holdings Secures FDA Fast Track Designation for CELZ-201-DDT - Advancing Breakthrough Therapy for Chronic Lower Back Pain • GlobeNewswire Inc. • 08/13/2025 01:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2025 08:45:55 PM
- Creative Medical Technology Holdings Receives Notice of Allowance for the Prevention and/or Treatment of Type 1 Diabetes Using Modulated Immune Cells • GlobeNewswire Inc. • 07/17/2025 01:15:00 PM
